A pharmaceutical company called Oblenio has started giving a new experimental drug, called LBL-051, to patients in the first phase of human testing. This drug is designed as a ‘tri-specific T cell engager,’ meaning it works by helping the body’s immune system target and remove two types of cells involved in autoimmune diseases: B cells and plasma cells. The goal is to reset the immune system in a way that could lead to long-term, drug-free remission for people with autoimmune diseases that don’t respond well to current treatments.
The study is open to the public, involves multiple medical centers, and is enrolling patients with various autoimmune conditions. The drug will be given as an injection under the skin to evaluate its safety, how well patients tolerate it, its effectiveness, and its impact on B cells, plasma cells, and specific biological markers in the body.
Dr. Ricardo Grieshaber-Bouyer, a professor and head of a clinical trial unit in Germany, explained that early laboratory research on LBL-051 showed it completely removes both B cells and plasma cells by targeting two proteins, CD19 and BCMA, while causing minimal side effects like inflammation. He believes this dual targeting approach could lead to a more thorough and consistent reset of the immune system compared to treatments that only target one type of cell.
Dr. Grieshaber-Bouyer also highlighted that the German regulatory agency, the Paul Ehrlich Institute (PEI), has approved a unique and carefully designed first-in-human trial. This design allows for quick yet safe evaluation of LBL-051 in multiple autoimmune diseases, with a strong focus on patient safety.
Dr. Tapan Maniar, the Chief Medical Officer of Oblenio, shared that this early-stage trial is a major advancement in developing T cell engager drugs for autoimmune conditions. The study aims to quickly gather important data in patients with high unmet medical needs by testing this off-the-shelf treatment approach.
He added that the company hopes to show LBL-051 can provide a broad and lasting reset of the immune system, and they are excited about the potential of targeting both CD19 and BCMA proteins.
Oblenio recently shared early research findings about LBL-051 at a major rheumatology conference in Europe.
Dr. Gunter Assmann, a rheumatology and immunology expert from Germany, stated that there are very few effective treatments available for autoimmune diseases, and many patients do not respond to current standard therapies. He emphasized that because of this unmet need, he and his team are prioritizing participation in this trial, as Oblenio’s research and focus on this potential breakthrough treatment are highly promising.